China’s pharmaceutical sector is currently being transformed into a high-quality and innovative-focused industry, reflected by the growth of new drug and clinical trial approvals in recent years.
This is being driven by factors such as a rapidly aging society, higher healthcare demands, drug regulation reforms, and increased investment inflows.
Healthcare is one of the most exciting sectors in China, growing above 10 percent annually with 2018 pharmaceutical imports approaching $15 billion.
Pharma14's monthly updated platform tracks the pharmaceutical landscape and pricing environment of the Chinese market.
14 Shenkar st.